Discover Veltassa®, a reliable and easy to use hyperkalaemia treatment with no sodium-associated risk1-12
I am practicing from:
Austria
Austria
Belgium
Germany
Ireland
Italy
Netherlands
Portugal
Spain
Switzerland
Other
I am residing in:
Austria
Austria
Belgium
Germany
Ireland
Italy
Netherlands
Portugal
Spain
Switzerland
Other
Bitte verwenden Sie als Benutzernamen die E-Mail Adresse, welche Sie bei der Registration angegeben hatten. Falls Sie das Passwort vergessen haben, können Sie sich einen Reaktivierungslink zustellen lassen. Alternativ ist für bereits registrierte Health Professionals auch eine Anmeldung mit der HPC-Card von FMH oder pharmaSuisse möglich.
Discover Veltassa®, a reliable and easy to use hyperkalaemia treatment with no sodium-associated risk1-12
Adverse events should be reported to the Vifor Pharma group.
safety@viforpharma.com
Veltassa® (patiromer sorbitex calcium) is a novel, next-generation, non-absorbed cation exchange polymer indicated for the treatment of hyperkalaemia in adults.1,2
It is manufactured using a suspension polymerisation process that results in insoluble spherical beads of uniform and controlled size.
Veltassa®’s smooth microbead structure and low swelling ratio may minimise undesirable GI effects and lead to improved tolerability for patients.2
Veltassa® increases faecal K+ excretion by exchanging Ca2+ for K+ in the lumen of the GI tract and reducing serum levels of this cation.1
Veltassa® has been designed to be fully ionised at the physiological pH of the colon, where the concentration of K+ in the GI tract is highest,2,4,5 for optimal ion exchange
Veltassa® has a 1.5−2-fold higher K+-binding capacity than other polymers2
Veltassa® is not absorbed and remains physically intact during its passage through the GI tract1
MIX
Mix 3 tablespoons of water with an entire sachet of Veltassa®, then stir
ADD
Add another 3 tablespoons of water and stir thoroughly. The powder will not dissolve and the mixture will look cloudy
DRINK
Drink immediately. If powder remains in the glass after drinking, repeat steps 2 and 3 to ensure the entire dose is taken
In a palatability questionnaire-based study in healthy volunteers, 90% of participants reported positive palatability experiences with Veltassa® in terms of odour and taste, suggesting that neither is likely to have an impact on patient acceptance or adherence.7
Timing of the daily dose is flexible but, as a precautionary measure, it should be separated by 3 hours from other oral medicines.
LUNCH
3H >
SNACK
3H >
DINNER
VELTASSA® can be administered with or without food. At least 3 hours should be left between taking Veltassa® and any other medication.
Veltassa® should be refrigerated prior to dispensing but can then be stored by patients below 25°C for up to 6 months. Veltassa® should not be used after the expiry date printed on the sachet.
Ca2+, calcium ions; GI, gastrointestinal; K+, potassium ions; Na+, sodium ions.
Veltassa® is indicated for the treatment of hyperkalaemia in adults1
1. Veltassa® SmPC. 2. Li L, et al. J Cardiovasc Pharmacol Ther 2016;21(5):456−65. 3. Bushinsky DA, et al. Clin J Am Soc Nephrol 2016;11(10):1769−76. 4. Noureddine L, Dixon BS. Clin Invest (Lond) 2015;5(10):805−23. 5. Sandle GI. Gut 1998;43(2):294−9. 6. Data on file. Healthcare Analytics (SHA), a Symphony Health Solutions Corporation (February 2019). 7. Brenner M, et al. ASHP 2016. 8. Bakris GL, et al. JAMA 2015;314(2):151−61. 9. Weir MR, et al. N Engl J Med 2015;372(3):211−21. 10. Bushinsky DA, et al. Kidney Int 2015;88(6):1427−33. 11. Pitt B, et al. Eur Heart J 2011;32(7):820−8. 12. Agarwal R, et al. Lancet 2019;394(10208):1540−50.